Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need
Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, currently has a dismal five-year survival rate of approximately 10% due to late diagnosis and a lack of efficient treatment options such as surgery. Furthermore, the majority of PDAC patients have surgically unresect...
Main Authors: | Geou-Yarh Liou, Crystal J. Byrd |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/9/2446 |
Similar Items
-
Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going
by: Alessandro Coppola, et al.
Published: (2023-05-01) -
Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives
by: Alessandro Coppola, et al.
Published: (2022-08-01) -
Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma
by: Tomonari Shimagaki, et al.
Published: (2023-11-01) -
Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma
by: Gennaro Nappo, et al.
Published: (2023-03-01) -
Fully Automatic Deep Learning Framework for Pancreatic Ductal Adenocarcinoma Detection on Computed Tomography
by: Natália Alves, et al.
Published: (2022-01-01)